76
|
McIntire PJ, Ginter PS, Irshaid L, Cui X, Chen Z, Shin SJ. Abstract P6-09-56: Tissue microarray (TMA) based immunohistochemical studies of lymphocyte-specific markers yield inaccurate results. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-09-56] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
|
77
|
Cui X, Hartanto Y, Zhang H. Advances in multicellular spheroids formation. J R Soc Interface 2017; 14:20160877. [PMID: 28202590 PMCID: PMC5332573 DOI: 10.1098/rsif.2016.0877] [Citation(s) in RCA: 274] [Impact Index Per Article: 39.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2016] [Accepted: 01/11/2017] [Indexed: 12/20/2022] Open
Abstract
Three-dimensional multicellular spheroids (MCSs) have a complex architectural structure, dynamic cell-cell/cell-matrix interactions and bio-mimicking in vivo microenvironment. As a fundamental building block for tissue reconstruction, MCSs have emerged as a powerful tool to narrow down the gap between the in vitro and in vivo model. In this review paper, we discussed the structure and biology of MCSs and detailed fabricating methods. Among these methods, the approach in microfluidics with hydrogel support for MCS formation is promising because it allows essential cell-cell/cell-matrix interactions in a confined space.
Collapse
|
78
|
Guo FM, Cui X, Wang KL, Wei JQ. Stretchable and compressible strain sensors based on carbon nanotube meshes. NANOSCALE 2016; 8:19352-19358. [PMID: 27845462 DOI: 10.1039/c6nr06804a] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Flexible strain sensors have promising applications in healthcare and human movement detection. Herein, we report stretchable and compressible strain sensors based on carbon nanotube meshes (CNTMs) with unique structures consisting of macroscopic grids and microscopic spider-web networks. The stretchable strain sensor shows good reliability for long cyclic tests and can be used for weak stimuli and large motion detection. The compressible strain sensor also shows good reliability after long cyclic tests and can be used to detect large strains induced by walking or running motion. Both the stretchable and compressible CNTM strain sensors are reliable and stable at detecting large stretching and compressing deformation.
Collapse
|
79
|
Yu J, Han J, Zhang J, Li G, Liu H, Cui X, Xu Y, Li T, Liu J, Wang C. The long noncoding RNAs PVT1 and uc002mbe.2 in sera provide a new supplementary method for hepatocellular carcinoma diagnosis. Medicine (Baltimore) 2016; 95:e4436. [PMID: 27495068 PMCID: PMC4979822 DOI: 10.1097/md.0000000000004436] [Citation(s) in RCA: 60] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver in adults worldwide. Several studies have demonstrated that long noncoding RNAs (lncRNAs) are involved in the development of various types of cancer, including HCC. These findings prompted us to examine the detectability of lncRNAs in blood samples from patients with HCC. In this study, we explored the expression levels of 31 cancer-related lncRNAs in sera from 71 HCC patients and 64 healthy individuals by reverse transcription and quantitative polymerase chain reaction (RT-qPCR). We found that 25 lncRNAs could be detected in the serum and that 7 had significantly different expression levels. A 2-lncRNA signature (PVT1 and uc002mbe.2) identified by stepwise regression showed potential as a diagnostic marker for HCC. The area under the receiver operating characteristic (ROC) curve was 0.764 (95% CI: 0.684-0.833). The sensitivity and specificity values of this serum 2-lncRNA signature for distinguishing HCC patients from the healthy group were 60.56% and 90.62%, respectively. The diagnostic ability of the combination of the serum 2-lncRNA signature with alpha-fetoprotein (AFP) was much greater than that of AFP alone. The expression levels of the 2 lncRNAs were associated with clinical parameters including tumor size, Barcelona Clinic Liver Cancer (BCLC) stage, and serum bilirubin.
Collapse
|
80
|
Sun LL, Chang W, Jiao LQ, Cui X, Dong G. Hepatic fibrosis and supersonic shear imaging in patients with different etiological chronic hepatic diseases. J BIOL REG HOMEOS AG 2016; 30:761-765. [PMID: 27655494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
The objective of the present study was to investigate whether hepatic fibrosis difference of supersonic shear imaging (SSI) value existed in patients with different etiological chronic hepatic diseases. Retrospective analysis was used to study chronic hepatitis. All the subjects were diagnosed by shear wave elastography and percutaneous liver biopsy. The shear moduli were analyzed to check whether any difference existed between groups. For the chronic hepatitis B, autoimmune hepatitis and fatty hepatitis, the shear moduli in S0 stage were (8.50±3.1)kPa, (9.41±2.5)kPa, (8.97±3.8)kPa; the shear moduli in S1 stage were (9.54±3.0)kPa, (10.42±5.1)kPa, (9.51±4.6)kPa; the shear moduli in S2 stage were (11.77±4.8) kPa, (13.25±5.6)kPa, (11.03±6.0)kPa; the shear moduli in S3 stage were (14.96±6.1)kPa, (19.03±7.8) kPa, (15.38±7.8)kPa; the shear moduli in S4 stage were (20.36±7.5)kPa, (24.99±9.5)kPa, (19.53±5.6)kPa. Shear wave elastography could measure the different etiological chronic hepatic diseases.
Collapse
|
81
|
Barnes S, Benton HP, Casazza K, Cooper SJ, Cui X, Du X, Engler JA, Kabarowski JH, Li S, Pathmasiri W, Prasain JK, Renfrow MB, Tiwari HK. Training in metabolomics research. I. Designing the experiment, collecting and extracting samples and generating metabolomics data. JOURNAL OF MASS SPECTROMETRY : JMS 2016; 51:ii-iii. [PMID: 27434812 DOI: 10.1002/jms.3672] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Metabolomics is perhaps the most challenging of the -omics fields, given the complexity of an organism's metabolome and the rapid rate at which it changes. When one sets out to study metabolism there are numerous dynamic variables that can influence metabolism that must be considered. Recognizing the experimental challenges confronting researchers who undertake metabolism studies, workshops like the one at University of Alabama at Birmingham have been established to offer instructional guidance. A summary of the UAB course training materials is being published as a two-part Special Feature Tutorial. In this month's Part I the authors discuss details of good experimental design and sample collection and handling. In an upcoming Part II, the authors discuss in detail the various aspects of data analysis.
Collapse
|
82
|
Yue Y, Wagner S, Medina-Kauwe L, Cui X, Zhang G, Shiao S, Sandler H, Fraass B. WE-FG-BRA-11: Theranostic Platinum Nanoparticle for Radiation Sensitization in Breast Cancer Radiotherapy. Med Phys 2016. [DOI: 10.1118/1.4957911] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
83
|
Cui X, Chen K, Xing H, Yang Q, Krishna R, Bao Z, Wu H, Zhou W, Dong X, Han Y, Li B, Ren Q, Zaworotko MJ, Chen B. Pore chemistry and size control in hybrid porous materials for acetylene capture from ethylene. Science 2016; 353:141-4. [DOI: 10.1126/science.aaf2458] [Citation(s) in RCA: 839] [Impact Index Per Article: 104.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2016] [Accepted: 05/05/2016] [Indexed: 01/18/2023]
|
84
|
Hou B, Cui X, Liu Y, Zhang W, Liu M, Sun YE, Ma Z, Gu X. Positive feedback regulation between microRNA-132 and CREB in spinal cord contributes to bone cancer pain in mice. Eur J Pain 2016; 20:1299-308. [PMID: 26919478 DOI: 10.1002/ejp.854] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/10/2016] [Indexed: 12/14/2022]
Abstract
BACKGROUND cAMP response element-binding protein (CREB)-dependent gene expression plays an important role in central sensitization. CREB-regulated transcription coactivator 1 (CRTC1) dramatically increase CREB-mediated transcriptional activity. microRNA-132 (miR-132), which is highly CREB-responsive, functions downstream from CREB/CRTC1 to mediate activity-dependent synaptic plasticity and in turn loops back to amplify CREB/CRTC1 signalling. This study aimed to investigate the positive feedback regulation between miR-132 and CREB in spinal cord in the maintenance of bone cancer pain. METHODS Osteosarcoma cells were implanted into the intramedullary space of the right femurs of C3H/HeNCrlVr mice to induce bone cancer pain. We further investigated effects of repeated intrathecal administration with Adenoviruses expressing CREB-siRNA or miR-132 antisense locked nucleic acid (LNA), respectively, on nociceptive behaviours and on the activity of CREB/CRTC1 signalling. RESULTS Intramedullary inoculation of osteosarcoma cells resulted in up-regulation of spinal p-CREB, CRTC1 and CREB-target genes (NR2B and miR-132). Repeated intrathecal administration with Adenoviruses expressing CREB-siRNA or miR-132 LNA-AS, respectively, attenuated bone cancer-evoked pain behaviours, reduced the activity of CREB/CRTC1 signalling and down-regulated CREB-target gene NR2B expression in spinal cord. CONCLUSIONS These findings suggest that activation of spinal CREB/CRTC1 signalling may play an important role in bone cancer pain. Interruption to the positive feedback regulation between CREB/CRTC1 and its target gene miR-132 can effectively relieved the bone cancer-induced mechanical allodynia and spontaneous pain. WHAT DOES THIS STUDY ADD?: The positive feedback regulation between CREB/CRTC1 and its target gene miR-132 in spinal cord plays an important role in bone cancer pain.
Collapse
|
85
|
Yue Y, Cui X, Bose S, Audeh W, Zhang X, Fraass B. Abstract P5-01-03: Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-01-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Triple-negative breast cancer (TNBC) is a highly diverse group of cancers, and may benefit from molecular-targeted therapies. This study aims to stratify prognosis of TNBC patients using pre-treatment 18F-FDG PET/CT, alone and with correlation to immunohistochemistry biomarkers.
Method: 200 consecutive TNBC breast cancer patients treated between 2008 and 2012 who received lumpectomy or mastectomy as primary treatment were retrieved. Among the full cohort, 79 patients had pre-treatment 18F FDG PET/CT scans. Immunostaining status (percentage and intensity) of basal biomarkers (EGFR, CK5/6), Ki-67, P53, and other clinicopathological variables (age, tumor size, pathological T/N stage, nuclear grade, and lymph node metastasis) were obtained. Three PET image features were evaluated: maximum uptake values (SUVmax), mean uptake (SUVmean) and target volume (SUVvol) defined by SUV>2.5. The relationships among tumor metabolic activities and clinicopathological factors were evaluated. All variables were analyzed versus disease-free survival (DFS) using univariate and multivariate Cox analysis, Kaplan-Meier curves and log-rank tests. The optimal cutoff points of variables were estimated using time-dependent survival receiver operating characteristic (ROC) analysis.
Results: All PET features significantly correlated with proliferation marker Ki-67 (all p<0.010). SUVmax stratified the prognosis of TNBC patients with optimal cutoff derived by ROC analysis (≤3.5 vs >3.5, AUC=0.654, p=0.006). Basal biomarkers EGFR and CK5/6 and image features SUVmax, SUVmean, SUVvol were significant associated with DFS in univariate Cox analysis, whereas SUVmax (p=0.001) and EGFR (p=0.001) were also significant in multivariate Cox analysis. To integrate prognosis of biological and imaging markers, patients were first stratified by EGFR into low (≤15%) and high (>15%) risk groups. Further, SUVmax was used as a variable to stratify the two EGFR groups. In the high EGFR group, patients with high FDG uptake (SUVmax>3.5) had worse survival outcome (median DFS=7.6 months) than those patients with low FDG uptake (SUVmax≤3.5, median DFS=11.6 months). In the low EGFR group, high SUVmax also indicated worse survival outcome (17.2 months) than low SUVmax (22.8 months). The risk stratification with integrative EGFR and PET was statistically significant with log-rank p<<0.001.
Multivariate Cox analysis for disease-free survivalVariablesHR (95% CI)p-valuePathology, T stage, ≤ 3 vs >32.337(0.428-7.384)0.148EGFR, ≤15% vs > 15%9.109(1.997-41.55)0.004CK5/6, ≤ 50% vs > 50%1.471(0.598-3.614)0.401SUVmax, ≤3.5 vs > 3.53.883(1.13-13.32)0.031
TNBC patient risk groups stratified by EGFR and SUVmax (with the median values of variables)Risk groups (EGFR>15, SUVmax>3.5)patient#DFS monthsEGFR %SUVmaxSUVmeanSUVvolKi-67%1 (-, -)1222.852.00.60.2342 (-, +)1517.258.94.37.2673 (+, -)1311.6502.72.60.9354 (+, +)377.66011.35.210.960
Conclusions: Pre-treatment 18F-FDG PET/CT imaging has significant prognostic value for predicting survival outcome of TNBC patients. Integrated with basal-biomarker EGFR, PET imaging can further stratify patient risks in the pre-treatment stage, and help select appropriate treatment strategies for individual patients.
Citation Format: Yue Y, Cui X, Bose S, Audeh W, Zhang X, Fraass B. Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-01-03.
Collapse
|
86
|
Wagner S, Yue Y, Cui X, Zhang G, Bingchen H, Li D, Medina-Kauwe L. Abstract P3-12-13: Radiation enhancement with cysteine coated platinum nanoparticles. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-12-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Radiation is the current choice treatment for non-operable metastatic breast-brain cancer. When cancer lesions are located in sensitive areas like the brain or have excessive amounts of metastatic sites, radiation usually proves to be a more viable option than excision. Ionizing (X-ray and gamma) radiation is non-selective and affects all the tissue it penetrates. In order to concentrate the dose on tumors, high energy radiation from multiple directions is typically used, reaching the highest dose where the radiation crosses. This type of multiple angle treatment minimizes the dose to normal tissue by increasing overall normal tissue irradiation. The objective is to achieve sufficient radiation in the tumor tissue to cause the DNA strands to break and to disrupt the reproduction and maintenance of cancer cells while keeping the damage to normal tissue in a reasonable range for tissue preservation.
Metal nanoparticles have shown promising results for reinforcing the radiation dose effect. High atomic number (Z) elements absorb a greater amount of radiation because the higher density raises the probability of interaction. The metal nanoparticles interact with the energy of the ionizing radiation by either scattering or absorbing, or accumulating the energy, thus increasing the number of DNA strand breaks in the nucleus of cells.
Methods: Four breast cancer cell lines (BT-474, MDA-231, BT-549 and MCF-7) were incubated with 1-2 nm platinum nanoparticles (0-1000 μg/mL) produced with a cysteine coating. 24 hours later cells were exposed to 2 Gy radiation with a C-arm (Toshiba Infinix VF-i/SP) using 125 KVP to deliver a spectrum of KeV low energy X-rays. After 24 hours the cells were washed and analyzed using a bioluminescence assay to assess cell proliferation based on ATP production.
Results: Of the four cell lines tested the BT-474 and BT-549 demonstrated limited reduction in cell proliferation at up to the highest treatment concentration 1000 μg/mL with no radiation exposure. As a result of the limited toxicity of the platinum nanoparticles the effect from increased radiation can be more readily observe when 2 Gy radiation is added resulting a in platinum nanoparticle dose dependent decrease in proliferation in the BT-474 cell line.
Nanoparticle Toxicity Concentration of Platinum Nanoparticles (μ/mL) 02505007501000MDA-2311.000±0.0050.995±0.0120.974±0.0130.979±0.0140.777±0.014BT-5491.000±0.0131.003±0.0091.003±0.0170.969±0.0170.894±0.009MCF-71.000±0.0140.960±0.0150.927±0.0220.851±0.0220.769±0.032BT-4741.000±0.0240.961±0.0290.957±0.0330.965±0.0630.985±0.065Table 1: Indexed values for cell proliferation for the BT-474 cell
Radiation Toxicity Concentration of Platinum Nanoparticles (μ/mL) 02505007501000*0 Gy1.000±0.0240.961±0.0290.957±0.0330.965±0.0630.985±0.0652 Gy1.027±0.0380.966±0.0230.908±0.0340.870±0.0310.799±0.037Table 2: Indexed values for cell proliferation for the BT-474 cell line 0 and 2 Gy radiation doses, 6 averages. * Student T-TEST P<0.05
Conclusions: At moderate doses of low energy radiation, a reduction in cell proliferation can be detected. This data supports follow-up experiments to add a targeting protein to facilitate uptake by cancer cells based on cell receptor expression. Experiments are current being done to utilize the HER2+ cell receptor upregulation to increase internalization of the particles to achieve a greater effect.
Citation Format: Wagner S, Yue Y, Cui X, Zhang G, Bingchen H, Li D, Medina-Kauwe L. Radiation enhancement with cysteine coated platinum nanoparticles. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-12-13.
Collapse
|
87
|
Medina-Kauwe L, Sims J, Taguiam M, Hanson C, Alonso-Valenteen F, Cui X, Wagner S, Sorasaenee K, Moats R, Marban E, Chung A, Gray H, Gross Z, Giuliano A. Abstract P6-17-05: A corrole nanobiologic crosses the blood-brain-barrier and recognizes triple negative breast cancer: Implications for targeting brain metastases. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-17-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Patients with breast cancer metastases to the brain on average survive less than one year. These tumors tend to be resistant to current therapies, and the majority of targeted therapeutics are unable to breach the blood brain barrier (BBB) to reach these tumors, thus improved alternatives are urgently needed.
Elevated cell surface levels of the human epidermal growth factor receptor subunit 3 (HER3) is associated with metastatic breast tumors, including those that spread to the brain. Elevated HER3 is also associated with resistance to a number of targeted therapies currently used in the clinic, including inhibitors of EGFR (lapatinib), HER2 (lapatinib, trastuzumab, T-DM1), HER2-3 (pertuzumab), and combination therapy.
Whereas a number of targeted therapies are currently used to combat peripheral breast tumors, the delivery of these molecules to brain metastases is limited by the blood brain barrier (BBB). This is exemplified by HER2+ breast tumors that metastasize to the brain: these tumors, while targetable outside of the central nervous system (CNS) by HER2 antibodies such as trastuzumab, are unreachable by these same antibodies because the HER2 subunit, though present on the brain endothelium, does not mediate antibody transcytosis across the blood vessel wall.
HER3, on the other hand, undergoes rapid transcytosis across the brain endothelium upon ligand binding, which normally occurs to mediate the delivery of neuregulin growth factors for neural growth and maintenance. We have developed a self-assembling nanobiological particle, HerMn, which uses HER3 as a portal for targeted entry of toxic molecules into tumor cells.
HerMn is a 10-20 nm diameter serum-stable particle comprised of a HER3-targeted cell penetration protein non-covalently assembled with a sulfonated manganese(III) corrole (S2Mn or Mn-corrole). Tumor-targeted toxicity by HerMn occurs by mitochondria membrane disruption and superoxide-mediated damage to the cytoskeleton. HerMn can also elicit tumor-selective detection by magnetic resonance imaging (MRI) due to the paramagnetic property of the corrole. HerMn distributes to the brain after systemic injection in mice, in addition to showing preferential homing and toxicity to subcutaneous tumors expressing the HER2-3 dimer. Interestingly, the Mn corrole is known to exhibit neuroprotective effects due to its antioxidant activity on normal tissue. Consistent with this, we have found that HerMn supports human cardiac cell survival ex vivo. Our studies interrogating the therapeutic potential of HerMn suggest that this nanobiologic bears the capacity for targeting toxicity to brain-metastatic breast tumors while sparing off-target tissue due to both its targeting capacity and ability to provide beneficial protective effects to normal tissue such as the brain and heart.
Citation Format: Medina-Kauwe L, Sims J, Taguiam M, Hanson C, Alonso-Valenteen F, Cui X, Wagner S, Sorasaenee K, Moats R, Marban E, Chung A, Gray H, Gross Z, Giuliano A. A corrole nanobiologic crosses the blood-brain-barrier and recognizes triple negative breast cancer: Implications for targeting brain metastases. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-17-05.
Collapse
|
88
|
Medina-Kauwe L, Sims J, Taguiam M, Hanson C, Alonso-Valenteen F, Cui X, Chung A, Gray H, Gross Z, Giuliano A. Abstract P6-13-10: Therapeutic efficacy of HER3-targeted nanobiologics on resistant tumors. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-13-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Elevated cell surface levels of the human epidermal growth factor receptor subunit 3 (HER3) are associated with resistance to a number of signal-blocking breast cancer treatments, including inhibitors of EGF-R (lapatinib), HER2 (lapatinib, trastuzumab, T-DM1), HER2-3 (pertuzumab), and combination therapy. Additionally, HER3 elevation has been identified on "untarget-able" tumors such as triple-negative breast cancer (TNBC), including TNBC with acquired resistance to EGF-R inhibition. Patients with such refractory tumors currently have limited treatment options and a poor prognosis. Moreover, as up to 70% of cases resist or acquire resistance to signal-blocking therapies, an alternative approach addressing this important clinical problem has the potential for significant clinical impact.
We have developed a protein construct, HerPBK10, which self-assembles with a variety of payloads (including nucleic acids, chemotherapy agents, and imaging agents) and uses HER3 as a portal for targeted entry into cells. In contrast to receptor-targeted antibodies and tyrosine kinase inhibitors currently used in the clinic, HerPBK10 circumvents the need to modulate signaling by inducing rapid entry of toxic molecules into tumor cells through receptor-mediated endocytosis and membrane penetration.
We have previously shown that nanobiological particles formed between HerPBK10 and therapeutic payloads can elicit targeted toxicity to HER2+ tumors due to the prevalence of HER2-3 heterodimers on the tumor cell surface, while sparing heart and liver tissue. The particles that form (20-40 nm dia.) exhibit stability in serum and no detectable immunogenicity. Here we show that such particles resolve breast tumor cells with acquired resistance to HER2 and/or EGFR inhibitors in contrast to trastuzumab, pertuzumab, and combination treatment. Additionally, therapeutic efficacy is augmented on resistant over parental tumor cells, due in part to the elevated HER3 expression associated with resistance to these inhibitors. Our studies in preclinical models show that these nanoparticles ablate the growth of tumors with both acquired and pre-existing resistance to trastuzumab. Moreover, we have found that signal-inhibitors currently used in the clinic, such as trastuzumab, effectively augment the efficacy of our nanobiologic on both naïve and inherently-resistant breast tumor cells, in part through induced elevation of HER3. Thus, current targeted molecules such as trastuzumab or lapatinib may act as adjuvants to enhance tumor cell-sensitivity to HerPBK10-particles. Such an approach may address the tumor-heterogeneity associated with resistance, and corner tumors for attack by our particles.
Citation Format: Medina-Kauwe L, Sims J, Taguiam M, Hanson C, Alonso-Valenteen F, Cui X, Chung A, Gray H, Gross Z, Giuliano A. Therapeutic efficacy of HER3-targeted nanobiologics on resistant tumors. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-13-10.
Collapse
|
89
|
Dietrich CF, Chiorean L, Potthoff A, Ignee A, Cui X, Sparchez Z. Percutaneous sclerotherapy of liver and renal cysts, comments on the EFSUMB guidelines. ZEITSCHRIFT FUR GASTROENTEROLOGIE 2016; 54:155-66. [PMID: 26854836 DOI: 10.1055/s-0041-106594] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Cystic lesions in the liver and kidneys are common incidental findings. They are generally benign and require no treatment. They can appear sporadically or as part of a syndrome, and are characterised by their anechoic structure and posterior enhancement in ultrasound imaging. Increased size, haemorrhage or infection of a cyst can lead to development of symptoms. Along with surgical options and laparoscopic cyst fenestration, ultrasound-guided sclerotherapy of symptomatic cysts represents an effective and safe minimally invasive treatment option.
Collapse
|
90
|
LI Y, Cui X, Qiu X, Ding C, Batool I. Management reference for nature reserve networks based on MaxEnt modeling and gap analysis: a case study of the brown–eared pheasant in China. ANIMAL BIODIVERSITY AND CONSERVATION 2016. [DOI: 10.32800/abc.2016.39.0241] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
91
|
Cao XB, Li YH, Fang F, Cui X, Yao YW, Wei JQ. High quality perovskite films fabricated from Lewis acid–base adduct through molecular exchange. RSC Adv 2016. [DOI: 10.1039/c6ra15378j] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
High quality CH3NH3PbI3 perovskite films without residual PbI2 are fabricated from the Lewis adduct of PbI2·xDMF through molecular exchange. The photovoltaic performances of the perovskite solar cells are thus improved significantly.
Collapse
|
92
|
Cui X, Dini S, Dai S, Bi J, Binder BJ, Green JEF, Zhang H. A mechanistic study on tumour spheroid formation in thermosensitive hydrogels: experiments and mathematical modelling. RSC Adv 2016. [DOI: 10.1039/c6ra11699j] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Thermo-reversible microgels to culture and harvest uniform-sized tumour spheroids with a narrow size-distribution.
Collapse
|
93
|
Wolf J, Hochmair M, Kattan J, Ang MK, Garon E, Groen H, Heist R, Ohashi K, Felip E, Reguart N, Garciac Campelo R, Soo R, Paz-Ares L, de Marinis F, Smit E, Giovannini M, Squires M, Cui X, Zhang Y, Tan D. 478TiP A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv532.62] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
94
|
Cui X, Liu Y, Wang B, Xian G, Liu X, Tian X, Qin C. Knockdown of GPR137 by RNAi inhibits pancreatic cancer cell growth and induces apoptosis. Biotechnol Appl Biochem 2015; 62:861-7. [PMID: 25471990 DOI: 10.1002/bab.1326] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2014] [Accepted: 11/20/2014] [Indexed: 12/13/2022]
Abstract
G-protein-coupled receptors (GPCRs), the largest family of cell-surface molecules involved in a number of biological and pathological processes, have recently emerged as key players in carcinogenesis and cancer progression. Orphan G protein-coupled receptors (oGPCRs) are a group of proteins lacking endogenous ligands. GPR137, one of the novel oGPCR genes, was discovered by homology screening. However, the biological role of GPR137 in cancers has not yet been discussed and is of great therapeutic interest. In this study, we knocked down GPR137 via a lentivirus system in two human pancreatic cancer cell lines BXPC-3 and PANC-1. Knockdown of GPR137 strongly inhibited cell proliferation and colony formation. Flow cytometry showed that cell cycle was arrested in the sub-G1 phase and apoptotic cells were significantly increased after GPR137 knockdown. Western blotting confirmed that GPR137 silencing induced apoptosis due to cleavage of PARP (poly ADP-ribose polymerase) and upregulation of caspase 3. Furthermore, lentivirus-mediated overexpression of GPR137 promoted the proliferation of PANC-1 cells, suggesting GPR137 as a potential oncogene in pancreatic cancer cells. Taken together, our results prove the importance of GPR137 as a crucial regulator in controlling cancer cell growth and apoptosis.
Collapse
|
95
|
Yue Y, Shiao S, Burnison M, Cui X, Chung A, Audeh W, Zhang X, Sandler H, Fraass B. Stratifying Prognosis of Triple-Negative Breast Cancer Patients Treated With Breast Conserving Therapy and Mastectomy Using Basal Biomarkers. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
96
|
Vogel T, Cohen J, Han B, Walts A, Zhang X, Karlan B, Cui X. The role of FOXC1 in clear cell ovarian carcinoma: Potential prognostic biomarker for aggressive disease? Gynecol Oncol 2015. [DOI: 10.1016/j.ygyno.2015.07.083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
97
|
Yang S, Li C, Xie Y, Cui X, Li X, Wei J, Zhang Y, Yu Y, Wang Y, Zhang S, Zhang Q, Sun D. Detection of functional polymorphisms influencing the promoter activity of the SAA2 gene and their association with milk production traits in Chinese Holstein cows. Anim Genet 2015; 46:591-8. [PMID: 26373797 DOI: 10.1111/age.12332] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/04/2015] [Indexed: 11/28/2022]
Abstract
Our previous RNA sequencing experiment showed that the serum amyloid A2 (SAA2) gene was one of the most promising candidates for milk protein and fat traits in dairy cattle. The SAA2 gene encodes an apolipoprotein related to high-density lipoproteins. To further validate its genetic effects, genotype-phenotype associations were performed in this study. Through resequencing of the entire coding region and the 5'-regulatory region of the SAA2 gene using pooled DNA of 12 unrelated sires, one novel 3-bp insertion-deletion and five previously reported SNPs were detected. These identified SNPs were genotyped and tested for association with five milk production-related traits in 717 Chinese Holstein cows. After Bonferroni correction for multiple t-tests, five of them were found to be statistically significant for milk yield, fat yield and protein yield (P < 0.0001~0.0053). Haplotype-based association analysis revealed a similar effect on fat yield and protein yield (P = 0.0005, P = 0.0032 respectively). Then, using luciferase report assay, the regulatory effect of the three SNPs located in the promoter region (c.-22G>A; c.17G>C; c.114G>A) was evaluated on transcriptional activity. In HEK-293 cell lines, we found that constructs GCG and AGG showed higher luciferase activity compared with GCA (P < 0.01, P < 0.01 respectively). Meanwhile, the prediction of the putative differential transcription factor binding site revealed that c.17G>C and c.114G>A caused the alteration in the transcription factor. Overall, the findings presented here provide the first evidence for associations of the SAA2 gene with milk fat and protein traits, which appears to be a key candidate for milk production traits in dairy cattle.
Collapse
|
98
|
Dummer R, Sandhu S, Hassel J, Muñoz E, Berking C, Gesierich A, Ascierto P, Esposito O, Carter K, Antona V, Radhakrishnan R, Cui X, Caponigro G, Jaeger S, Demuth T, Miller Jr W. 3310 LOGIC2: Phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanoma. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31828-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
99
|
Adamczyk L, Adkins JK, Agakishiev G, Aggarwal MM, Ahammed Z, Alekseev I, Alford J, Anson CD, Aparin A, Arkhipkin D, Aschenauer EC, Averichev GS, Banerjee A, Beavis DR, Bellwied R, Bhasin A, Bhati AK, Bhattarai P, Bichsel H, Bielcik J, Bielcikova J, Bland LC, Bordyuzhin IG, Borowski W, Bouchet J, Brandin AV, Brovko SG, Bültmann S, Bunzarov I, Burton TP, Butterworth J, Caines H, Calderón de la Barca Sánchez M, Campbell JM, Cebra D, Cendejas R, Cervantes MC, Chaloupka P, Chang Z, Chattopadhyay S, Chen HF, Chen JH, Chen L, Cheng J, Cherney M, Chikanian A, Christie W, Chwastowski J, Codrington MJM, Contin G, Cramer JG, Crawford HJ, Cudd AB, Cui X, Das S, Davila Leyva A, De Silva LC, Debbe RR, Dedovich TG, Deng J, Derevschikov AA, Derradi de Souza R, Dhamija S, di Ruzza B, Didenko L, Dilks C, Ding F, Djawotho P, Dong X, Drachenberg JL, Draper JE, Du CM, Dunkelberger LE, Dunlop JC, Efimov LG, Engelage J, Engle KS, Eppley G, Eun L, Evdokimov O, Eyser O, Fatemi R, Fazio S, Fedorisin J, Filip P, Finch E, Fisyak Y, Flores CE, Gagliardi CA, Gangadharan DR, Garand D, Geurts F, Gibson A, Girard M, Gliske S, Greiner L, Grosnick D, Gunarathne DS, Guo Y, Gupta A, Gupta S, Guryn W, Haag B, Hamed A, Han LX, Haque R, Harris JW, Heppelmann S, Hirsch A, Hoffmann GW, Hofman DJ, Horvat S, Huang B, Huang HZ, Huang X, Huck P, Humanic TJ, Igo G, Jacobs WW, Jang H, Judd EG, Kabana S, Kalinkin D, Kang K, Kauder K, Ke HW, Keane D, Kechechyan A, Kesich A, Khan ZH, Kikola DP, Kisel I, Kisiel A, Koetke DD, Kollegger T, Konzer J, Koralt I, Kosarzewski LK, Kotchenda L, Kraishan AF, Kravtsov P, Krueger K, Kulakov I, Kumar L, Kycia RA, Lamont MAC, Landgraf JM, Landry KD, Lauret J, Lebedev A, Lednicky R, Lee JH, LeVine MJ, Li C, Li W, Li X, Li X, Li Y, Li ZM, Lisa MA, Liu F, Ljubicic T, Llope WJ, Lomnitz M, Longacre RS, Luo X, Ma GL, Ma YG, Madagodagettige Don DMMD, Mahapatra DP, Majka R, Margetis S, Markert C, Masui H, Matis HS, McDonald D, McShane TS, Minaev NG, Mioduszewski S, Mohanty B, Mondal MM, Morozov DA, Mustafa MK, Nandi BK, Nasim M, Nayak TK, Nelson JM, Nigmatkulov G, Nogach LV, Noh SY, Novak J, Nurushev SB, Odyniec G, Ogawa A, Oh K, Ohlson A, Okorokov V, Oldag EW, Olvitt DL, Pachr M, Page BS, Pal SK, Pan YX, Pandit Y, Panebratsev Y, Pawlak T, Pawlik B, Pei H, Perkins C, Peryt W, Pile P, Planinic M, Pluta J, Poljak N, Poniatowska K, Porter J, Poskanzer AM, Pruthi NK, Przybycien M, Pujahari PR, Putschke J, Qiu H, Quintero A, Ramachandran S, Raniwala R, Raniwala S, Ray RL, Riley CK, Ritter HG, Roberts JB, Rogachevskiy OV, Romero JL, Ross JF, Roy A, Ruan L, Rusnak J, Rusnakova O, Sahoo NR, Sahu PK, Sakrejda I, Salur S, Sandweiss J, Sangaline E, Sarkar A, Schambach J, Scharenberg RP, Schmah AM, Schmidke WB, Schmitz N, Seger J, Seyboth P, Shah N, Shahaliev E, Shanmuganathan PV, Shao M, Sharma B, Shen WQ, Shi SS, Shou QY, Sichtermann EP, Singaraju RN, Skoby MJ, Smirnov D, Smirnov N, Solanki D, Sorensen P, Spinka HM, Srivastava B, Stanislaus TDS, Stevens JR, Stock R, Strikhanov M, Stringfellow B, Sumbera M, Sun X, Sun XM, Sun Y, Sun Z, Surrow B, Svirida DN, Symons TJM, Szelezniak MA, Takahashi J, Tang AH, Tang Z, Tarnowsky T, Thomas JH, Timmins AR, Tlusty D, Tokarev M, Trentalange S, Tribble RE, Tribedy P, Trzeciak BA, Tsai OD, Turnau J, Ullrich T, Underwood DG, Van Buren G, van Nieuwenhuizen G, Vandenbroucke M, Vanfossen JA, Varma R, Vasconcelos GMS, Vasiliev AN, Vertesi R, Videbæk F, Viyogi YP, Vokal S, Vossen A, Wada M, Wang F, Wang G, Wang H, Wang JS, Wang XL, Wang Y, Wang Y, Webb G, Webb JC, Westfall GD, Wieman H, Wissink SW, Witt R, Wu YF, Xiao Z, Xie W, Xin K, Xu H, Xu J, Xu N, Xu QH, Xu Y, Xu Z, Yan W, Yang C, Yang Y, Yang Y, Ye Z, Yepes P, Yi L, Yip K, Yoo IK, Yu N, Zawisza Y, Zbroszczyk H, Zha W, Zhang JB, Zhang JL, Zhang S, Zhang XP, Zhang Y, Zhang ZP, Zhao F, Zhao J, Zhong C, Zhu X, Zhu YH, Zoulkarneeva Y, Zyzak M. Precision Measurement of the Longitudinal Double-Spin Asymmetry for Inclusive Jet Production in Polarized Proton Collisions at sqrt[s]=200 GeV. PHYSICAL REVIEW LETTERS 2015; 115:092002. [PMID: 26371644 DOI: 10.1103/physrevlett.115.092002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/20/2014] [Indexed: 06/05/2023]
Abstract
We report a new measurement of the midrapidity inclusive jet longitudinal double-spin asymmetry, A_{LL}, in polarized pp collisions at center-of-mass energy sqrt[s]=200 GeV. The STAR data place stringent constraints on polarized parton distribution functions extracted at next-to-leading order from global analyses of inclusive deep-inelastic scattering (DIS), semi-inclusive DIS, and RHIC pp data. The measured asymmetries provide evidence at the 3σ level for positive gluon polarization in the Bjorken-x region x>0.05.
Collapse
|
100
|
Chen C, Wang Q, Gao Y, Lu Z, Cui X, Zheng T, Liu Y, Li X, He X, Zhang X, Duan C, Li T. Photothrombosis combined with thrombin injection establishes a rat model of cerebral venous sinus thrombosis. Neuroscience 2015; 306:39-49. [PMID: 26297898 DOI: 10.1016/j.neuroscience.2015.08.020] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2014] [Revised: 08/08/2015] [Accepted: 08/11/2015] [Indexed: 10/23/2022]
Abstract
OBJECTIVE Cerebral venous sinus thrombosis (CVST) is a rare but life-threatening disease and an animal model for in-depth study of CVST is needed. This study aimed to develop a rat model suitable for studying clinically relevant aspects of CVST and investigating its dynamic pathophysiological changes during a 7-day period. METHOD A photothrombosis method was used to create a rat sinus-vein thrombosis model. A spot size-adjustable Diode Pumped Solid State laser (DPSS) combined with thrombin injection occluded the rostral and caudal superior sagittal sinus (SSS). The model was used to evaluate pathophysiological changes at different time points over 7 days. Evans Blue dye injection was used to detect alterations in blood-brain barrier (BBB) permeability. Brain water content was also measured. Moreover, we examined changes in brain infarct volume, neurological function, as well as histology after induction of CVST. RESULT CVST in rats significantly altered BBB permeability, consistent with the development of brain edema. It was accompanied by an increase in brain infarct volume and deficits in neurological function that began on day 1, peaked on day 2, and typically improved by day 7 due to the neuroprotective effects of angiogenesis and gliocyte proliferation. CONCLUSION In this study, we describe a rat model that produces clinically relevant pathophysiology and pathology that will facilitate evaluation of therapeutic regimens for CVST. Furthermore, our results indicate a period of optimal clinical intervention for patients with CVST, which may reduce the probability of dependency and death.
Collapse
|